Merck Receives 2014 ENERGY STAR Sustained Excellence Award From US Environmental Protection Agency
Merck (MSD) has received an ENERGY STAR 2014 Partner of the Year — Sustained Excellence Award from the US Environmental Protection Agency (EPA) for its continued improvement of energy performance and leadership in energy management in both the pharmaceutical and industrial sectors.
Merck has been an ENERGY STAR partner since 1995 and recognized by the EPA for 9 consecutive years, twice as Partner of the Year and now a seventh time for Sustained Excellence.
“Managing energy well is consistent with Merck's philosophy of being a responsible company,” said Rodney Freeman, vice president, Global Facilities Management, Merck. “We are using greener sources of energy and reducing greenhouse gas emissions. Our partnership with ENERGY STAR helps us focus on our main goal of reducing energy consumption. We believe the greenest kilowatt is the one not used.”
The award recognizes four Merck manufacturing sites that have achieved ENERGY STAR rankings in the top 25% of pharmaceutical plant energy performance nationwide: Arecibo, Puerto Rico, Cleveland, Tenn., Las Piedras, Puerto Rico; and Elkhorn, Neb.
Also achieving certification this year were two buildings at Merck's corporate headquarters in Whitehouse Station, NJ, Merck’s office buildings in Upper Gwynedd, Pa., West Point, Pa., and for the first time, Cokesbury, NJ In addition, four sites in Europe were recognized for meeting the ENERGY STAR Challenge for Industry by reducing their energy intensity by 10%over a 5-year period. The sites recognized are Heist, Belgium; Swords, Ireland; Cramlington, UK; and Mirabel, France.
“Merck has earned EPA’s highest ENERGY STAR award — the 2014 Partner of the Year — Sustained Excellence Award — because of its unwavering commitment to helping consumers become increasingly more energy efficient,” said EPA Deputy Administrator Bob Perciasepe.
www.merckresponsibility.com
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.